Is LEU a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on HALEU and the DOE expansion award, with revenue (ttm) at ~$474 million (latest quarter +14% YoY). The bear case rests on centrus is heavily dependent on government funding and contracts: its HALEU program runs on DOE awards and extensions, and a multi-billion-dollar expansion relies on continued federal support and appropriations that can shift with politics. Analysts covering it are spread from $167.00 to $340.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Centrus is heavily dependent on government funding and contracts: its HALEU program runs on DOE awards and extensions, and a multi-billion-dollar expansion relies on continued federal support and appropriations that can shift with politics. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $167.00, +45.3% from the $114.94 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

HALEU and the DOE expansion award. Centrus runs the only US-licensed HALEU enrichment plant and has delivered HALEU to the Department of Energy, including a 900-kilogram milestone delivery in 2025. The most optimistic analyst target on LEU is $340.00, +195.8% from the $114.94 price. That figure is only reachable if this thesis works close to its best case.

Centrus is heavily dependent on government funding and contracts: its HALEU program runs on DOE awards and extensions, and a multi-billion-dollar expansion relies on continued federal support and appropriations that can shift with politics. Customer concentration is high, with a limited set of utilities and the US government driving revenue, so the loss or delay of a single contract can swing results. Quarterly results are lumpy: the third quarter of 2026 (report expected around November 4) carries a consensus EPS of only about $0.01 on revenue of about $65 million, after a strong second quarter. The business is exposed to enrichment (SWU) and uranium price cycles, which are volatile and can compress margins. Scaling up centrifuge cascades is capital-intensive and technically demanding, raising execution and timeline risk, and the company faces competition from larger global enrichers and from other US funding recipients. Sentiment risk is real: the stock is down about 71% over one year as nuclear and uranium names sold off together, and it still trades at about 55x trailing and 31x forward earnings, leaving it sensitive to any disappointment. The most pessimistic published target is $167.00, +45.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

US nuclear-fuel company that sells enriched uranium to utilities and runs the only US-licensed HALEU enrichment plant, riding the reshoring of enrichment and the ban on Russian uranium imports.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (HALEU and the DOE expansion award) stalling in the reported numbers rather than in the narrative, the risk above (centrus is heavily dependent on government funding and contracts: its HALEU program runs on DOE awards and extensions, and a multi-billion-dollar expansion relies on continued federal support and appropriations that can shift with politics) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Centrus Energy supplies nuclear fuel and fuel-cycle services. Its Low-Enriched Uranium segment sells enriched uranium to utilities that run nuclear reactors under long-term contracts, and its Technical Solutions segment houses its American Centrifuge work, including a US-government HALEU enrichment contract and engineering services. Centrus runs the only US-licensed HALEU enrichment facility, in Piketon, Ohio, producing the high-assay fuel that advanced reactors need.

The company trades as LEU on the NYSE American exchange, officially Centrus Energy Corp., headquartered in Bethesda, Maryland. The ticker comes from low-enriched uranium, its core product. It is available at every major US brokerage with commission-free trading, and many brokers also offer fractional shares so you can invest a fixed dollar amount.

No. Centrus Energy does not currently pay a dividend on its common stock, so its yield is 0%. The company is reinvesting in expanding US enrichment capacity rather than returning cash to shareholders, so any return would come from share-price changes rather than dividend income. The figure is current as of October 2026; verify against Centrus's investor relations page.